Letter by Keidar and Gamliel-Lazarovich regarding article, "Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo- and active-controlled phase 2 trial"

Circulation

Volumn 125, Issue 18, 2012, Pages

  Keidar, Shlomo ^a   Gamliel Lazarovich, Aviva ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE INHIBITOR; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; FAD 286; LCI 699; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; KNOCKOUT MOUSE; LETTER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE;

ALDOSTERONE SYNTHASE; BLOOD PRESSURE; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84860760534     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.080341     Document Type: Letter

References (2)

1. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: Results of a randomized, double-blind, placebo-and active-controlled phase 2 trial. Circulation. 2011;124:1945-1955.
2. Gamliel-Lazarovich A, Gantman A, Coleman R, Jeng AY, Kaplan M, Keidar S. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens. 2010;28:1900 -1907.